Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.
You may also be interested in...
Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution
As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.
No Homerun, But A Base Hit For Teva's Laquinimod
Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.
No Homerun, But A Base Hit For Teva's Laquinimod
Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.